ArticleAbdominal radiology (New York)2026
Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The Role of the Mesopancreas in Pancreatic Neuroendocrine Neoplasms.Journal of clinical medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe mesopancreas (MP), the dorsal area of the pancreas, is infiltrated in the majority of patients with pancreatic ductal adenocarcinoma of the pancreatic head (hPDAC) and is associated with an increased risk of incomplete resection. Current radiographic resectability criteria primarily focus on tumor involvement of major peripancreatic vessels. However, the dorsal resection margin, represented by the mesopancreas, is not explicitly considered in current staging concepts. The aim of this study was therefore to standardize a quantitative radiographic assessment of the mesopancreas and to correlate these findings with histopathology.
methodsRadiographic parameters of the primary tumor and the mesopancreas were evaluated in 173 patients with hPDAC who underwent upfront surgery. Patients were stratified according to NCCN anatomical resectability criteria. Mesopancreatic dimensions (mm) and density (HU) were analyzed on preoperative multidetector computed tomography (MDCT). Nineteen patients served as a reference group. Histopathological evaluation followed the Leeds Pathology Protocol (LEEPP).
results124 patients (71.7%) were classified as primary resectable and 49 (28.3%) as borderline resectable. Mesopancreatic infiltration was present in 125 patients (72.3%). Resectability classification was not associated with mesopancreatic infiltration (p = 0.344; OR 1.5). The median density of the mesopancreas in hPDAC patients was 3 HU. Increased mesopancreatic density correlated with histopathologically confirmed mesopancreatic infiltration (p = 0.005), with an optimal threshold of -9 HU. In subgroup analysis, this association remained significant in primary resectable patients (p = 0.021) but not in borderline resectable tumors (p = 0.780). Additionally, higher mesopancreatic density was associated with poorer disease-free survival in primary resectable patients (p = 0.040).
conclusionIncreased mesopancreatic density on preoperative MDCT correlated with histopathologically confirmed mesopancreatic tumor infiltration. Radiographic assessment of mesopancreatic density may therefore provide additional information for preoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.